A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) (PULSAR) 2018-12-13T18:56:04+00:00

Clinical Trials

Dec. 13, 2018

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) (PULSAR)

  • Study Sponsor: Acceleron Pharma, Inc.
  • Institution: Acceleron Pharma, Inc.
  • Start Date: Wednesday, June 27, 2018
  • End Date: Tuesday, March 31, 2020
  • Design: 
    • Placebo-controlled
    • Background treatment allowed
  • Age range (years): 18 to 125
  • Type of PH
    • IPAH
    • Heritable – APAH
    • CTD – APAH
    • CHD – APAH
    • Toxic – APAH
  • Study Duration for individual patient: 24 weeks
  • Contact:  https://clinicaltrials.gov/ct2/show/NCT03496207